linjc16/ctgov huggingface dataset:
Hypoglycemic and Hyperglycemic Disorders

Study Overview
=================
Brief Summary
-----------------
Definition of low birth weight: Low birth weight infants are those born weighing less than 2500 g. These are further subdivided into: Very Low Birth Weight : Birth weight <1,500 g Extremely Low Birth Weight : Birth weight <1,000 g Their survival is directly related to birth weight, with approximately 20% of those between 500 and 600 g and>90% of those between 1,250 and 1,500 g surviving. Perinatalcare has improved the rate of survival of low birth weight infants.

Detailed Description
-----------------
Causes of low birth weight: Premature birth Intrauterine growth restriction, which are most often Due to different placental problems and health problems of the mother or new-born RISK FACTORS: Age: Teen mothers have a much higher risk of having VLBW infant. Multiple birth babies are at increased risk of being VLBW because they often are premature. More than 50% of twins and other multiple gestations are VLBW if <15 years Maternal health: Women exposed to drugs, alcohol, and cigarettes during pregnancy are more likely to have low birth weight babies. Mothers of lower socioeconomic Race: African-American babies are twice as likely as Caucasian to be very low birth weight

Official Title
-----------------
Glycemic Disorders in Low Birth Weight Babies

Conditions
-----------------
Hypoglycemia in Newborn Infants, Hyperglycemia

Intervention / Treatment
-----------------
* Diagnostic Test: random blood sugar


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All neonates admitted to neonatology unit From 0-28 days Weighting less than 2500gm Exclusion Criteria: Any neonate weighting more than 2500 gm

Ages Eligible for Study
-----------------
Maximum Age: 28 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: random blood sugar|do random blood sugar at 0 hour - 2 hours- 4 hours and after 6 hours|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glycemic disorders in low birth weight | to detect the prevelance of hypoglycemia and hyperglycemia in low birth weight babies by random blood sugar test | one year |
Management of Sexual Dysfunction With Bioresonance Technique

Study Overview
=================
Brief Summary
-----------------
Bioresonance is the big promise of the medical technology of the future because it stimulates the self-regenerating system of the body by affecting the body's most essential procedures. The big advantage is that its multiple and there are no harmful side effects. This therapy teaches something to the body what in a younger and healthier state it had already Bioresonance is based on the scientific principle that metabolism within cells is influenced by one's electromagnetic field. We start to use bioresonance technology in management of erectile dysfunction , premature ejaculation, decreased libido.

Official Title
-----------------
Management of Male Sexual Dysfunction With Bioresonance Technique, a New Egyptian Device

Conditions
-----------------
Sexual Dysfunction, Erectile Dysfunction, Premature Ejaculation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: erectile dysfunction Premature ejaculation Decreased libido Exclusion Criteria: nil
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient satisfaction |  | 2-6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Penile duplex study |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Erectile dysfunction, sexual dysfunction, bioresonance
Stem Cells for Treating Critical Ischemia

Study Overview
=================
Brief Summary
-----------------
Collection of bone marrow blood Selection of mononuclear cells dilution with albumin injection into the calf muscles through 40 shots

Detailed Description
-----------------
About 500cc of blood are collected from the iliac bone marrow under epidural anesthesia.In the cell therapy lab this blood is harvested and mononuclear cells are separated.This procedure takes roughly 4 hours.After dilution in albumin (40cc)the mononuclear cells are injected into the calf muscles through 40 shots.This procedure is indicated for patients with lower limb ischemia on whom all the others known therapies have failed

Official Title
-----------------
the Use of Autogenous Adult Stem Cells in the Treatment of Critical Ischemia

Conditions
-----------------
Critical Limb Ischemia, Ischemic Ulcers

Intervention / Treatment
-----------------
* Procedure: stem cells transplant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fontaine's classification grade 3 and 4 patients Exclusion Criteria: Record of cancer in the last 5 years Over 80 years Diabetic retinopathy

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: stem cells transplant|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Suppress pain and heal ischemic ulcers |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| improve quality of life |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rest pain, ischemic ulcers
Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if combination therapy with a statin medication and two additional agents that work differently than statin medications can further lower the so-called bad cholesterol. One therapy is a prescription drug approved by the Food and Drug Administration to treat high cholesterol (Welchol). The other therapy is Minute Maid Heart Wise orange juice. This study juice is available in supermarkets and contains plant sterols that have been shown to lower cholesterol.

Detailed Description
-----------------
Coronary heart disease (CHD) is the primary cause of morbidity and mortality in the United States. Lowering LDL cholesterol in both patients with and without CHD reduces coronary events and death. Statin medications are the primary mechanism of lowering LDL cholesterol, but some patients do not reach their goal LDL with maximum tolerated statin doses and must utilize combination therapy to further lower cholesterol. Additionally, some patients prefer to utilize natural mechanisms to lower cholesterol. This prospective, double-blinded, randomized study will compare plant sterol (natural cholesterol treatment) with placebo in patients treated with combination statin and colesevelam therapy.

Official Title
-----------------
Evaluation of Plant Sterol and Placebo on Low-density Lipoprotein Concentrations in Hyperlipidemic Patients Treated With Combination Statin and Colesevelam Therapy.

Conditions
-----------------
Hyperlipidemia, Dyslipidemia

Intervention / Treatment
-----------------
* Drug: Minute Maid Heart Wise orange juice
* Drug: Welchol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of high cholesterol being treated with a statin LDL cholesterol greater than 100 Ability to swallow large tablets Exclusion Criteria: Diabetes Use of other medications to treat high cholesterol History of liver disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Minute Maid Heart Wise orange juice|nan|
|Drug: Welchol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| LDL cholesterol |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Triglycerides, HDL cholesterol, total cholesterol, C-reactive protein, Apolipoprotein B |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antilipemic agents, hyperlipidemia
Urinary Concentration and Diluting Ability in Patients With Chronic Renal Disease and/ or Hypertension

Study Overview
=================
Brief Summary
-----------------
The investigators want to test the hypothesis that patients with chronic renal disease have a poorer ability to preserve water after being thirsty and a poorer ability to excrete water after a load of fluid. They presume that these abilities become poorer when renal insufficiency progresses. The investigators further hypothesize that patients with hypertension also have a decreased ability to concentrate and dilute urine.

Official Title
-----------------
Urinary Concentration and Diluting Ability in Patients With Chronic Renal Disease or Hypertension

Conditions
-----------------
Renal Insufficiency, Chronic, Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with chronic renal insufficiency, aged between 18 and 65, both men and women Creatinine clearance between 30-59 ml/min Patients with hypertension, aged between 18 and 65, both men and women; hypertension is defined as a mean arterial blood pressure in the daytime that is more than 140/90 mm Hg. Healthy volunteers, aged between 18 and 65, both men and women Exclusion Criteria: Clinical signs or history of disease in the heart, lungs, liver, brain, and endocrine organs Cancer Alcohol abuse Medicine abuse Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dialysis patients<br> | |
| with or wthout glucose added to dialysis fluid<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Urine concentration ability, chronic renal insufficiency, hypertension, aquaporin2, Patients with chronic renal insufficiency, Patients with hypertension, Healthy volunteers
Microcirculation in Perforator Flaps. Enhancing Tissue Survival

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to assess the microcirculatory changes in the distal part of the perforator flap using ICG fluorescence angiography.

Detailed Description
-----------------
Perforator flaps are increasingly used in reconstructive surgery both as pedicled and free flaps, mostly because of reduced donor site morbidity and superior aesthetic result. However, the there is still much to learn about the hemodynamic changes within these flaps.The aim of the present study is to assess the microcirculatory changes in the distal part of the perforator flap using ICG fluorescence angiography.

Official Title
-----------------
Microcirculation in Perforator Flaps. Enhancing Tissue Survival

Conditions
-----------------
Reconstructive Surgery, Microcirculation

Intervention / Treatment
-----------------
* Drug: Indocyanine green (ICG)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients submitted to elective abdominoplasty Exclusion Criteria: body mass index < 30 kg/m2 morbidly obese patients with comorbidity such as diabetes vascular disease smokers patients < 18 years, and patients using anti-coagulant therapy pregnant severe hepatic insufficiency were excluded and a history of allergic reactions to ICG and iodide.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Indocyanine green (ICG)|a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean pixel intensity using dynamic laser-induced-fluorescence-videoangiography | Perfusion measurements were conducted intraoperatively by assessing microcirculation using the technique of dynamic laser-induced-fluorescence-videoangiography (IC-VIEW, PULSION Medical Systems AG, Munich, Germany). | dec. 2008--des 2010 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
perforator flaps
High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19

Study Overview
=================
Brief Summary
-----------------
In this study, we aimed to compare, retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone with those to whom low-dose long-term (2x 40 mg) systemic methylprednisolone was administered.

Official Title
-----------------
Comparison of High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19 - Retrospective Cross-sectional Study

Conditions
-----------------
Short-term (3 Days) High-dose (1000 mg) Systemic Methylprednisolone

Intervention / Treatment
-----------------
* Behavioral: systemic methylprednisolone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between June 1, 2020 and February 1, 2021, hospitalized in the General intensive care unit of Biruni University Medical Faculty Hospital with the diagnosis of COVID 19; patients over 18 years of age; (for the diagnosis of COVID 19; Identification of SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR) in nasopharyngeal swab or sputum samples and Abnormal lung computed tomography finding (CT) scan finding with <90% oxygen saturation at rest (bilateral, subpleural, peripheral ground glass opacities) Exclusion Criteria: Patients with a diagnosis of steroid allergy or developing during treatment; pregnant or lactating women; Patients with active malignancy; Patients taking any immunosuppressive agent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 105 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| short-term (3 days) high-dose (1000 mg) systemic methylprednisolone<br>retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone | Behavioral: systemic methylprednisolone<br>* short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone<br>|
| low-dose long-term (2x 40 mg) systemic methylprednisolone<br>retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom low-dose long-term (2x 40 mg) systemic methylprednisolone | Behavioral: systemic methylprednisolone<br>* short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| C Reaktif Protein | level of C Reaktif Protein | 15 DAYS |
Nutrition and Soccer for Pediatric Overweight and Obesity

Study Overview
=================
Brief Summary
-----------------
This study will examine whether two months of youth soccer, combined with a single brief behavioral/nutritional intervention, can reduce BMI in 5th grade overweight or obese females.

Detailed Description
-----------------
Female overweight and obese public school students will be recruited during the summer of 2006 based on FitnessGram testing done by graduate students at MSU during their prior (4th grade) school year. After receiving informed consent from parent/child, the subjects will be checked for height/weight and other screening criteria, then exposed to 2005 My Pyramid for Kids, Tips for Families information, and watch a short 8 minute DVD that discusses the importance of exercise and fitness by way of interviewing two club level female soccer players of equivalent age. Subjects will then be randomly assigned to fall youth soccer in Starkville, or spring youth soccer, after first phase data collection occurs in November, 2006.

Official Title
-----------------
Multi Intervention Approach to Pediatric Overweight and Obesity: A Randomized Control Group Trial

Conditions
-----------------
Obesity, Overweight

Intervention / Treatment
-----------------
* Procedure: Youth Soccer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: obese or overweight 4th grade public school student in Starkville Exclusion Criteria: unable to run or physical disease or disability

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Youth Soccer|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BMI |  | 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| My Tips for Families Quiz |  | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obesity, overweight
The Effect of Perioperative Lidocaine Intravenous Infusion on Postoperative Recovery After Spine Surgery.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effectiveness of perioperative Lidocaine intravenous infusion in reducing postoperative pain for spine surgery patients.

Detailed Description
-----------------
Study design: this study used a prospective, randomized, double-blinded, and placebo-controlled clinical trial. Sixty patients scheduled for a spine surgery will be randomly assigned to two groups. Lidocaine group will receive an intravenous bolus injection of lidocaine 1.5 mg/kg before intubation, followed by 2 mg/kg/h continuous infusion during the operation. Placebo group will receive the same dosage of saline at the same time. Analgesic requirement will be monitored using patient-controlled Analgesia (PCA protocol: demand dose is 2 mg of morphine, lockout 5 min, maximum dose 15 mg per hour). Forty-eight hours after surgery, we will check the morphine consumption in two groups. Quality of recovery after surgery will be assessed using Q0R15 questionnaire.

Official Title
-----------------
The Effect of Perioperative Lidocaine Intravenous Infusion on Postoperative Recovery After Spine Surgery.

Conditions
-----------------
Spinal Diseases

Intervention / Treatment
-----------------
* Drug: Lidocaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: spine surgery with general anesthesia Exclusion Criteria: lidocaine allergy hepatic disease dementia or cognitive decline

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Lidocaine<br>Patients will receive Lidocaine drip during spine surgery | Drug: Lidocaine<br>* Lidocaine drip during surgery<br>|
| Placebo Comparator: Placebo<br>Patients will receive placebo during spine surgery | Drug: Lidocaine<br>* Lidocaine drip during surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pain | Quality of recovery after surgery will be assessed using Q0R15 questionnaire and analgesic requirement will be monitored using PCA | 24 hours postop |